Sharon Hesterlee's Blog – October 2012 Archive (2)

Better, Faster, Now!

These are the words that best describe PPMD’s research plan.



  1. We aim to put better drugs into development for clinical trials because we can’t afford the failures.
  2. We apply funding strategically to increase the speed of testing new drugs.
  3. We prioritize and fund the testing in Duchenne of drugs that are already approved for other purposes.



Everything we do goes through this filter to make sure that we are achieving one of these…

Continue

Added by Sharon Hesterlee on October 11, 2012 at 11:00am — 4 Comments

Positive Phase 1 trial results for SMT C1100 in Duchenne (Summit PLC)

Following closely on the heels of the good news about Sarepta’s exon 51 skipping strategy, PPMD is pleased to report that Summit…

Continue

Added by Sharon Hesterlee on October 10, 2012 at 10:30am — 13 Comments

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service